What happened
A TD Cowen survey of 80 biopharma executives, reported by Axios, found AI-powered tools reduce preclinical drug development costs and timelines by up to 70%. This shift drives investment in advanced software, genomic sequencing, and predictive models, aiming to expand experimental therapies. Brendan Smith, TD Cowen's director of life sciences equity research, noted AI enables massive data generation, improving promising drug candidate odds. The survey projects a 10% increase in new drug development programs over three to five years, with an estimated $1 billion in additional industry investment.
Why it matters
This 70% reduction in preclinical costs and timelines directly impacts pharmaceutical R&D budgets and project pipelines. For R&D teams and investors, this mechanism allows for a projected 10% increase in new drug development programs and an estimated $1 billion in additional industry investment. This follows recent reports of surging AI drug deals in China, intensifying competitive pressure on US pharmaceutical companies to accelerate innovation. Procurement teams should prioritise evaluating AI platforms that offer demonstrable cost and time efficiencies in early-stage research.
